Twitter | Search | |
Pharmaxis
A pharmaceutical research company with approved products in world markets and a drug discovery program focused on treatments for fibrosis and inflammation.
152
Tweets
159
Following
206
Followers
Tweets
Pharmaxis retweeted
Proactive Australia Sep 11
Pharmaxis features in APAC’s top 100 most innovative pharma companies report via
Reply Retweet Like
Pharmaxis Jul 24
Multiple potential disease treatments under the microscope at Pharmaxis. Read about progress in our latest quarterly report.
Reply Retweet Like
Pharmaxis May 8
Pharmaxis welcomes US FDA committee’s recommendation on use of Bronchitol in CF via
Reply Retweet Like
Pharmaxis May 8
welcomes positive recommendation from Committee advising the FDA on the use of Bronchitol for adult cystic fibrosis patients in the United States.
Reply Retweet Like
Pharmaxis Apr 29
See details of progress with the drug discovery programs and latest company news in our Quarterly report
Reply Retweet Like
Pharmaxis Feb 24
Pharmaxis sees progress in Boehringer Ingelheim’s clinical trial in patients with NASH via
Reply Retweet Like
Pharmaxis Feb 21
First subject dosed in the Pharmaxis phase 1 clinical trial of a drug discovery to treat severe fibrosis and cancer.
Reply Retweet Like
Pharmaxis retweeted
Stockhead Feb 21
Fatty liver disease drug maker Pharmaxis adds pancreatic cancer to lineup
Reply Retweet Like
Pharmaxis retweeted
Proactive Australia Feb 21
Pharmaxis begins phase one clinical trial of compound targeting pancreatic cancer via
Reply Retweet Like
Pharmaxis Feb 21
Pleased to announce the launch of our Phase 1 clinical trial which is taking a new approach to tackling pancreatic cancer.
Reply Retweet Like
Pharmaxis Jan 30
Pharmaxis well funded as potential partners assess its anti‐fibrotic mechanisms via
Reply Retweet Like
Pharmaxis Jan 29
Key developments outlined in the Quarterly Report including our leading position in NASH clinical research, next program to start phase 1 and reimbursement for Bronchitol in Russia.
Reply Retweet Like
Pharmaxis Jan 17
Great to see ’ leading research in NASH highlighted.
Reply Retweet Like
Pharmaxis retweeted
KALKINE Jan 17
The company believes that its inhibitor program is now ready to enter phase 2 clinical studies. Following this news, the share price of the company increased by 8 percent on ASX as on 17 January 2019.
Reply Retweet Like
Pharmaxis retweeted
AusBiotech Jan 17
Pharmaxis updates on LOXL2 studies
Reply Retweet Like
Pharmaxis retweeted
Proactive Australia Jan 16
Pharmaxis LOXL2 program phase 2 ready after completion of 13-week toxicity studies via
Reply Retweet Like
Pharmaxis Dec 19
announces New Drug Application for Bronchitol in USA
Reply Retweet Like
Pharmaxis Dec 12
Pharmaxis reveals first sales of Aridol® in US following successful relaunch via
Reply Retweet Like
Pharmaxis Dec 12
An asthma diagnostic developed by notches up first distributor sales in the USA.
Reply Retweet Like
Pharmaxis retweeted
Proactive Australia Nov 22
Pharmaxis advancing partnership talks for LOXL2, and increasing anti fibrotic applications via
Reply Retweet Like